

Our Ref. No. : BSE/LODR/2024/0459

Date : 12<sup>th</sup> February, 2024

To,  
Corporate Relationship Department,  
BSE Limited,  
14<sup>th</sup> Floor, P.J. Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

**BSE Equity Scrip Code : 530665**

Dear Sirs,

**SUB : Outcome of Board Meeting**

With reference to the above subject, we hereby submit the following outcome of the Meeting of the Board of Directors held today, February 12, 2024 at 5:00 p.m. at the Registered Office of the Company concluded at 5:20 p.m.:

The Board considered and approved unaudited Standalone Financial Statement for Quarter and Nine months ended 31<sup>st</sup> December, 2023 along with Limited Review Report.

You are requested to take the same on your record.

Thanking you,

Yours faithfully,

**For, Zenith Healthcare Limited**

MIHIR SATISHBHAI SHAH  
Digitally signed by MIHIR  
SATISHBHAI SHAH  
Date: 2024.02.12 17:25:02 +05'30'

**(Mihir S. Shah)**

**Company Secretary & Compliance Officer**

**Membership No. : A41922**

UNAUDITED STANDALONE IND AS COMPLIANT FINANCIAL RESULT  
FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

SR.NO.	PARTICULARS.	QUARTERS ENDED			NINE MONTHS ENDED		FINANCIAL YEAR
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	ENDED 31/03/2023
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
	<b>INCOMES</b>						
I	Revenue from Operations	389.16	349.35	366.15	1140.18	1147.96	1312.94
II	Other Business Income	6.25	4.46	11.59	15.21	24.20	37.59
III	Total Income (I + II)	395.41	353.81	377.74	1155.39	1172.16	1350.53
	<b>EXPENSES.</b>						
(a)	Cost of materials consumed	199.13	134.34	203.47	487.47	608.16	753.14
(b)	Purchase of Stock in Trade.	5.52	0.01	5.60	61.38	11.57	12.59
(c)	Changes of Inventories of Finished Goods, Work in Progress, Work in Trade.	1.48	29.19	19.61	62.32	98.60	41.32
(d)	Employees Cost.	42.89	39.99	35.84	124.77	110.40	155.12
(e)	Finance Cost	0.53	0.49	0.09	1.10	0.57	0.73
(f)	Depreciation and Amortisation Expenses	5.21	5.51	6.56	15.89	20.60	28.02
(g)	Other Expenses	130.73	132.69	96.30	356.35	292.39	347.80
	<b>TOTAL EXPENSES (IV (a to f))</b>	<b>385.49</b>	<b>342.22</b>	<b>367.47</b>	<b>1109.28</b>	<b>1142.29</b>	<b>1338.72</b>
V	<b>Profit/(Loss) before Exceptional Items and Tax. (III-IV)</b>	<b>9.92</b>	<b>11.59</b>	<b>10.27</b>	<b>46.11</b>	<b>29.87</b>	<b>11.81</b>
VI	Exceptional Items. & Extraordinary Item	-	-	-	-	-	-
VII	<b>Profit/ (Loss) Before Tax. (V-VI)</b>	<b>9.92</b>	<b>11.59</b>	<b>10.27</b>	<b>46.11</b>	<b>29.87</b>	<b>11.81</b>
	<b>TAX EXPENSES.</b>						
(a)	Current Tax.	-	-	-	-	-	3.15
(b)	Deffered Tax.	-	-	-	-	-	0.88
	<b>Total Tax Expenses.</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4.03</b>
IX	<b>NET PROFIT / (LOSS) FOR THE PERIOD</b>	<b>9.92</b>	<b>11.59</b>	<b>10.27</b>	<b>46.11</b>	<b>29.87</b>	<b>7.78</b>
X	Other Comprehensive Income	-	-	-	-	-	-
XI	<b>Total Comprehensive Income (IX+X)</b>	<b>9.92</b>	<b>11.59</b>	<b>10.27</b>	<b>46.11</b>	<b>29.87</b>	<b>7.78</b>
XII	<b>Paid up Equity Share Capital (Amount in lacs) Rs. 10 Face value per share)</b>	<b>537.39</b> Re. 1/-					
XIII	Other Equity Capital (Reserve & Surplus)	-	-	-	-	-	185.82
XIV	<b>Earning Per Share (In Rupees) from Continuing Operations (Not Annualized).</b>						
(i)	Basic.	0.018	0.022	0.019	0.086	0.056	0.014
(ii)	Diluted.	0.018	0.022	0.019	0.086	0.056	0.014

**NOTES:**

- The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on February 12, 2024
- The Company has only single Reportable Business Segment in terms of requirements of Ind AS 108.
- During the Quarter and Nine Months ended on December 31, 2023, 1 complaint were received and attended at the same time 0 compliant were pending at the end of the quarter.
- Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group's disclosure.
- These financial statement are prepared in accordance with Indian Accounting Standards (Ind AS) under the historical cost convention on the accrual basis except for certain financial instrument which are measured at fair values, the provisions of the Companies Act, 2013 ('Act') (to the extent notified) and guidelines issued by the Securities and Exchange Board of the India (SEBI). The Ind AS are prescribed under section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies ( Indian Accounting Standards ) Amendment Rules, 2016.

DATE : 12.02.2024

PLACE : AHMEDABAD

AJAY  
RATILAL  
PANDHI  
Digitally signed  
by AJAY RATILAL  
PANDHI  
Date: 2024.02.12  
11:58:50 +05'30'



BY ORDER OF THE BOARD OF DIRECTORS OF  
For, Zenith Healthcare Limited

(Mahendra C. Raycha)  
CHAIRMAN & MANGING DIRECTOR  
DIN : 00577647



# A.R. PANDHI & ASSOCIATES

CHARTERED ACCOUNTANTS

104, 1<sup>st</sup> Floor, Shitiratna Complex, Nr. Hotel Radisson Blu,  
Panchwati Cross Road, Ellisbridge, Ahmedabad - 380 006  
E-mail: [pandhi77@rediffmail.com](mailto:pandhi77@rediffmail.com). Tel.:(O) 2644 2000/4004 9676

Date : 12<sup>th</sup> February, 2024

To,  
The Board of Directors,  
Zenith Healthcare Limited

We have reviewed the accompanying statement of unaudited financial results of **Zenith Healthcare Limited** for the quarter and nine months ended **December 31, 2023**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place : Ahmedabad  
Date : 12.02.2024



Chartered Accountants  
Firm's Registration No.: 118057W  
AJAY RATILAL Digitally signed by AJAY  
RATILAL PANDHI  
Date: 2024.02.12 12:20:39  
+05'30'  
PANDHI  
(AJAY R. PANDHI)  
(Proprietor)  
(Membership No. 102616)  
UDIN : 24102616BJZYSK3139